Background: Circulatory assist devices are applied to support patients with end-stage heart failure or circulatory collapse. Extracorporeal membrane oxygenation (ECMO) and ventricular assist device (VAD) are the two devices that are commonly used in these situations. However, in patients undergoing ECMO, complications occur more frequently and are more severe than in those with VAD, especially in patients with coagulopathy. The cause of coagulopathy is seldom reported; therefore, the current prospective study was designed to compare the coagulation status between patients who received ECMO and bridged VAD thereafter. Methods: The cases for our study were collected between December 2005 and January 2010. A total of 21 patients with VAD were enrolled. Seven patients received initial ECMO support and were subsequently shifted to VAD. Use of blood transfusion products by patients was recorded during application of ECMO and VAD. Thrombelastography (TEG) was performed pre-ECMO and pre-VAD, and thereafter to 1 week post-VAD implantation. The relevant parameters that were examined included coagulation time (R: resting, K: kinetics, seconds), angle (a, degrees), maximal amplitude (MA, mm), clot strength (G, dynes/cm 2 ), and estimated percent lysis in 30 minutes (LY30, %). Coagulation status and average unit per day of blood transfusion at pre-VAD and post-VAD status were recorded. TEGs of pre-VAD and post-VAD implantation were compared in order to determine the frequency of bleeding. Results: Average results from seven cases were incorporated into the current analysis. The patient transfusion requirement was reduced after implantation of the VAD. The TEG of post-VAD implantation was improved from the earlier pre-VAD results (ECMO status). Ultimately, TEG resulted in significant differences in R, K, angle, MA, and G, postoperatively. Conclusion: Coagulopathy of patients with VAD improved after bridging from ECMO, which can be attributed to improved coagulation factor and platelet function. Thus, bleeding complications are reduced.
Introduction
In the last 20 years, the use of circulatory assist devices has increased rapidly. These devices were designed to support patients with end-stage heart failure or circulatory collapse. Two commonly used devices are the extracorporeal membrane oxygenation (ECMO) unit and the ventricular assist device (VAD). ECMO supports cardiopulmonary function, including hemodynamic stability and gas exchange, and can be implemented rapidly and with ease. Hence, it was widely used in the event of acute cardiopulmonary collapse. However, certain complications can arise while using ECMO, including problems with bleeding and coagulopathy.
VAD is well suited to bridge a patient with end-stage heart disease until heart transplantation (bridge to heart transplantation) or recovery (bridge to recovery). 1 Complications associated with VAD use can include bleeding and thromboembolism. 2 However, blood transfusions in patient post-VAD implantation are required less frequently than those in patients using an ECMO device.
Although both of these devices provide support following circulatory collapse, the ECMO device can be implemented at a faster rate than VAD. Consequently, the ECMO device is frequently used in patients with acute hemodynamic deterioration. It can then be replaced with a VAD in cases that require extended device support.
In general, thrombelastography (TEG) has firmly established that coagulation status differs in patients using ECMO and VAD devices.
3 Therefore, the current study used TEG to monitor continuously coagulation status in patients as they transitioned from ECMO to VAD, because TEG is able to better determine the improvement during coagulation.
Methods
This study was carried out prospectively after getting study consent forms. Study cases were collected between December 2005 and January 2010 at our medical center, and a total of 21 patients with VAD were enrolled. Seven patients initially received ECMO support and were subsequently shifted to VAD. Gender, age, and diagnosis of patients were recorded, and each patient received VeA mode ECMO insertion from the right or left femoral vessel. In less than 1 week, use of ECMO was discontinued and patients were shifted to VAD. After the VAD was implemented, an anticoagulant protocol was followed. If the patient received the VAD of Levitronix, heparin infusion was started if the chest tubes transported less than 50 cc/h every 2e3 hours. Activated coagulation time (ACT) was kept between 160 and 180 seconds. Four days after VAD was initiated, activated partial thromboplastin time (APTT) was maintained at 1.3e1.6 times the normal range, and an antiplatelet aggregation agent was added (aspirin 81e325 mg/d). Pump flow was retained at approximately 4e5 LPM, with a speed of 3000e4000 RPM. If the case involved a Berlin heart setup, heparin infusion was initiated at 12e24 hours postoperatively if bleeding was controlled (<50 mL/h) and platelet count was more than 80,000/mL. APTT was at approximately 50e60 seconds on Postoperative Day 1, and 60e80 seconds for 2 days postoperatively if the platelet count was more than 100,000/mL. Dipyridamole 150 mg once per day was administered at Postoperative Day 2, and aspirin 50 mg twice per day was added at Postoperative Day 4. A vitamin K antagonist was taken orally if enteral feeding was possible. The International Normalized Ratio was maintained between 3.0 and 3.5.
Complications associated with study admission were documented.
The number of blood transfusions for each patient was recorded during ECMO and VAD. Blood products included fresh frozen plasma (FFP), cryoprecipitate, and platelet. Coagulation data stayed within a predetermined range: Hct >30 or Hb >10, and platelet number >50,000/mm. 4 The blood products were infused and the data were corrected according to the normal range. Total blood products were evaluated during ECMO and VAD to understand each patient's bleeding tendency further.
TEG was used to examine patient coagulation profile, beginning with initiation of ECMO until 1 week post-VAD implantation. Meanwhile, pre-ECMO TEG was also documented to determine the baseline coagulation status of each patient. Parameters of this documentation included coagulation time (R: resting time, K: kinetics, seconds), maximal amplitude (MA, mm), angle (degrees), clot strength (G, dynes/cm 2 ), and estimated percent lysis in 30 minutes (LY30, %).
Different factors are involved in the process of coagulation, including clotting time, kinetics, strength, and lysis. 5 The TEG graphic presentation included clot formation and subsequent lysis, and whole blood coagulation was assessed under low shear conditions. Blood was injected into a heated cup (<37 C). A suspended pin with a wire connected to a detector was inserted into the cup; the result was recorded by the detector under pin movement. The cup and pin were rotated at an angle of 4 45 0 every 10 seconds, and, when a fibrin clot occurred, the pin of the cup with the fibrineplatelet complex rotated with the cuvette. The graph curve increased until maximal clot firmness occurred and decreased when lysis was observed.
In the TEG graph ( Fig. 1) , R represents resting time, K is kinetics time, a is angle, MA is maximal amplitude, G is clot strength (kd/sc), and LY30 is percentage of lysis during an interval of 30 minutes. Each value of the TEG parameter of ECMO and VAD was compared with pre-ECMO values. The final ECMO value obtained was considered as the ECMOrelated coagulopathy total. After VAD setup was completed, TEG was used to compare with ECMO coagulation status, to determine any change in coagulation.
The TEG examination was self-pay, and patients signed a consent form approved by our medical center prior to their participation in the study. 
Statistical analysis
The data were analyzed by SPSS statistical software (IBM, Version 18.0). Continuous variables are expressed as median (minimum value e maximum value) and were compared between ECMO status and VAD setup over the course of 7 days using the Wilcoxon rank sum test. A p value of <0.05 was considered statistically significant.
Results
Seven patients (four men and three women) were eligible for study inclusion. Median participant age was 48 years (range: 3e55 years). Two participants were diagnosed with dilated cardiomyopathy(DCM), two with ischemic cardiac myopathy (ICM), one with chronic heart failure (CHF), and one with myocarditis; one was in unstable condition due to coronary artery disease (CAD) with cardiogenic shock. All uses of ECMO employed a venousearterial configuration with femoral cannulation. The ECMO status was less than 1 week in duration for each case prior to shifting over to VAD. Five patients received Levitronix VAD. Left atrium venous drainage was cannulated from the right upper pulmonary vein, and the arterial tip was cannulated at the ascending aorta. Two patients received the Berlin heart VAD. Left ventricle (LV) venous drainage was from apical cannulation and the arterial tip fixation was at the ascending aorta.
Two patients did not suffer from coagulopathy-related complications, such as gastrointestinal (GI) bleeding, wound oozing, or ecchymosis. Three patients suffered from ECMO wound oozing and received medical reintervention to address the bleeding. One presented with upper GI bleeding and one with hematuria that was under medical treatment during ECMO. One patient presented with skin ecchymosis and observation was suggested after VAD setup (Table 1) .
Due to blood component consumption and anticoagulant agent use, a tendency bleeding was noted in patients. All seven cases received blood product transfusions according to the criteria and clinical requirements to maintain the balance of coagulation. Each ECMO case received, at a minimum, FFP (4 U), cryoprecipitate (10 U), and platelet pheresis (4 U). During the 1 week of VAD, daily averages for each individual of the maximal requirement in FFP, cryoprecipitate, and platelet pheresis were only 2, 8, and 2 U, respectively. A significant reduction of blood transfusions was noted during VAD use as compared with ECMO use ( Table 2) .
The TEG document included R, K, angle, MA, G, and LY30. Prior to ECMO and VAD, ECMO status was recorded (Table 3) . Measured variables during VAD were similar to ECMO status in individual patients.
In order to compare the overall change in each patient, a preoperative/postoperative ratio was calculated (Table 2) . On average, the R and K values were predominantly under 1.00; however, the MA, angle, and G were greater than 1.00. Generally, in patients with VAD, R and K times were shorter, whereas MA, angle, and G were greater, as compared with ECMO status.
The results of TEG from pre-ECMO, ECMO status (pre-VAD), and VAD during the targeted 1 week were documented. Generally, the seven cases revealed normal median TEG at pre-ECMO, including a median R value of 5.20 minutes , G 3191.50 kd/sc, and LY30 0.30%. The significant difference of TEG change was found from the pre-ECMO to ECMO status.
The ECMO shift to VAD occurred after 1 week, at which time additional TEG follow-up was performed. The value of R decreased to a median of 12.10 minutes at VAD Day 1 from 11.30 minutes at ECMO status. Median reported values were 8.90, 11.50, 9.50, 9.10, 10.90, and 9.40 minutes at VAD Days 2, 3, 4, 5, 6, and 7, respectively ( Fig. 2A) .
The K value decreased to a median of 3.60 minutes at VAD Day 1 from 5.20 minutes at ECMO status. At VAD Days 2, 3, 4, 5, 6 and 7, median values were 3.00, 5.50, 3.70, 2.70, 3.40, and 2.90 minutes, respectively, for each individual (Fig. 2B) .
The MA value increased to a median of 54.10 mm at VAD Day 1. At VAD Days 2, 3, 4, 5, 6, and 7, the reported values were 58.40, 56.30, 60.10, 61.10, 61.20, and 64.90 mm, respectively, for each individual (Fig. 2C) .
The angle was found to be similar to MA. (Fig. 2D) . The G value also increased to 6388.71, 7386.07, 6942.9, 8040.00, 8205.90, 9360.20, and 9122.90 kd/sc from VAD Days 1 to 7 (Fig. 2E) .
LY30 changed from 0.30% to 0.00% at VAD Day 1. At VAD Days 2, 3, 4, 5, 6, and 7, the value was 0.48%, 0.20%, 1.60%, 3.50%, 3.80%, and 3.40%, respectively, for each individual (Fig. 2F ).
Discussion
VAD was beneficial for myocardial contractile improvement and for obtaining heart chamber geometry.
6e8 Meanwhile, the reversal of the downregulation of b receptor was also observed in heart failure after device implantation; therefore, inotropic agent sensitivity was also increased. 9 The VAD was designed with a centrifugal pump, incorporating an arterial and a venous cannula. The arterial cannula was placed over the aorta, and the venous cannula was placed over the apex of the heart or the left atrium. No supplemental oxygen was provided (via an oxygenator); therefore, this device was only suitable for normal lung gas exchange.
A potentially severe complication of ECMO is bleeding. Exposure of blood to a rough surface without endothelium can induce strong shear and hemolysis, especially in the oxygenator. On the other hand, inflammatory response is also triggered by coagulation, hemolysis, and thromboembosis, all of which can injure vital organs. 10 Hence, it is very important to maintain the APTT at 1.3e1.6 times the normal range, and ACT at approximately 160e180 seconds.
There are two types of VAD pumps: pulsatile and continuous flow. The new flow pump is smaller in size, generates no noise, and has demonstrated long-term durability. These factors have allowed the patient to ambulate and return to daily activities more easily. After VAD implantation, improved Left ventricle ejection fraction (LVEF) and decreased Left ventricle end-diastolic diameter (LVED) occurred more rapidly than prior to VAD implantation.
11
ECMO and VAD were both composed of a circulatory circuit, and coagulation activities were also enhanced due to the tubing system, which affected important components such as fibrinopeptides, plasmin inhibitors, or protein C. However, there was substantial variation in bleeding severity of those patients using ECMO and VAD. Overall, there were fewer resulting blood transfusions in patients using VAD than in those with ECMO. 12 In the past, the most well-known application in hepatic and cardiac surgery was TEG-guided transfusion of blood components. 13 Thereafter, TEG-guided transfusion became less popular due to its long-term analysis and scarce reproducibility. Gradually, the device was improved, as evidenced by the newer, smaller size of the device, and a reduced time for analysis. Similar to any surgery that had the potential for massive blood loss, TEG was the standard choice for transfusion of blood components. TEG is able to analyze from clot formation through lysis and can pinpoint the insufficiency within the coagulation cascade. Any insufficiency may result from fibrinogen, platelet dysfunction, or anomalies in the coagulation proteases. Minimizing these blood components, while still ensuring their correct composition, is critical to avoid potentially hazardous immune responses. 14 Patients with ECMO are at a high risk for development of coagulopathy. However, the cause of their bleeding can be difficult to identify using traditional coagulation tests such as prothrombin time (PT), APTT, and platelet counts, which has prompted further analyses. TEG appears to be a better choice to monitor clot development and overall stabilization. In the ECMO group, the most common etiology of bleeding is platelet dysfunction. 15 The centrifugal pump of ECMO can cause hemolysis, which will induce increased free hemoglobin and decreased haptoglobin. The free red blood cells can cause increased systemic vascular resistance, peripheral vascular resistance, and platelet dysfunction, particularly 3 days after ECMO being connected to the circuit. Alternatively, platelet count may fall approximately 50% due to hemolysis. On average, if the ECMO was used for approximately 1 week, Packed red blood cells (PRBC) 0.5e1 U and platelet 0.5e2 U are required daily. Then, platelet 1.06 U in venovenous (VV) ECMO and 1.57 U in venoarterial (VA) ECMO were used daily. 16 In our study, the mean platelet transfusion per day was 0.86e1.33 U, which is similar to the general mean consumption of platelets. After shifting to VAD, the usage of blood transfusion unit decreased significantly.
At first, TEG was used for liver transplantation. Twenty-five years later, it was also used as an important part of cardiac surgery due to coagulopathy in the heartelung machine. The artificial heart was developed for the transitional phase of heart transplantation. This device has certain advantages over the ECMO, namely coagulopathy. In order to monitor the change of coagulopathy, TEG was used for this examination.
The advantages of ECMO over an artificial heart (VAD) include a simple insertion technique, avoidance of sternotomy incision, and reduced cost. However, its disadvantages include limited long-term support; hemolysis; patient immobilization; increased chance of bleeding, stroke, and infection; limited decompression of the LV; and an increased afterload. Bridgeto-bridge is a concept for patients with cardiogenic shock. Patients also suffered from comorbidities during ECMO support. Consequently, to avoid a high risk of comorbidity, implantable VAD should be considered for long-term support. 17 Successful coagulopathy associated with ECMO was greater than that associated with VAD, because of the long tubing system and oxygenator that accompanied the use of ECMO. In addition, ECMO circuit often promotes the formation of platelet aggregates and the formation of clots in other organs. Hemolysis is related to the ECMO oxygenator and nonendothelial surface of the circuit. 18 Clots in the circuit promote the activation of complement, white blood cells, cofactors, and platelets. 19 Consumptive coagulopathy was found, including prothrombin activation fragment, fibrinogen, platelet counts, and thrombineantithrombin Ⅲ complex, especially during the first 48 hours. 20 VAD presents similarities to an extracorporeal circuit and encounters similar complications to those seen with the use of ECMO. In the study of Steinlechner et al, it was demonstrated that platelet dysfunction might be present in most patients with VAD. 21, 22 Endothelial and coagulation systems were first activated 2 hours into the postoperative period. 20 The extrinsic pathway (tissue factor) was accentuated due to endothelial dysfunction when using VAD. 23, 24 However, coagulopathy in VAD is less severe than in ECMO, due to the lack of an oxygenator.
TEG offers a complete coagulation examination, including cofactor function, platelet function, and clot lysis. 15 This examination is generally used in patients undergoing ECMO. The ECMO tube and oxygenator contain rough surfaces, and when the body touches the surface a coagulation response is triggered. Implications of clot formation include the induction of multiple embolisms and stroke. Heparin is often infused to ameliorate potential coagulation problems. ACT was checked as part of coagulation function; however, ACT could not represent the complete status of coagulation. TEG is suitable for monitoring coagulation.
Currently, many patients with end-stage heart disease are seeking a heart transplant. Complications associated with ECMO often occur more than 2 weeks after surgery in a posttransplant setting. Consequently, an artificial heart (VAD) is often suggested in part because VAD generally has fewer coagulation complications than ECMO. TEG was applied for coagulation change from ECMO to VAD.
A prolonged R value may indicate poor coagulation factor trigger function. The current study showed that R value was high in ECMO status and decreased after VAD insertion. Significant differences were found between pre-VAD and VAD insertion at VAD Days 1, 2, 4, and 7. The function of coagulation factor may be improved after VAD. Similarly, prolonged K value (the time of kinetics clot formation of coagulation factor) is indicative of poor clot formation in the beginning. Significant differences between pre-VAD and VAD insertion were found at VAD Days 1, 2, 4, 6, and 7 ( Table 4) .
The angle indicates the rate of clot formation, and thus poor angle may be indicative of slow clot formation. For example, in the current study, the angle value was increased after VAD insertion and resulted in a faster coagulation time. This result may be explained by less consumption or normal platelet function. MA represents the thickness of whole blood in the ECMO tube. This procedure involved the interaction of the coagulation factor and platelets. Poor MA may mean a reduced platelet count or a poor platelet function. In our study, a significant difference was noted at VAD Days 2, 6, and 7. The value of clot strength G was similar to MA. A poor G value indicates platelet dysfunction and thrombocytopenia. Significant differences between pre-VAD and VAD insertion were observed in patients with a VAD at 2, 4, 6, and 7 days after procedure. The improvement in coagulation complications was considered to represent stable clot formation. Stronger clot formation will prevent the spread of emboli and limit hemorrhage tendency.
The ECMO setup induced severe coagulopathy arising from TEG and many assessment parameters showed significant difference from pre-ECMO status. In ECMO status, poor coagulation factor and platelet function were induced due to inflammatory response, and thrombocytopenia was found due to massive rough surface consumption. This resulted in the need for massive blood transfusion to restrict consumption of coagulation factor and platelet, which often induced more severe complications. After shifting from ECMO to VAD, TEG appeared to promote normal coagulation. Meanwhile, the strength of clot formation was suspected to be an important factor for TEG improvement. VAD decreased bleeding risk and maintain nearly normal coagulation function. Consequently, it may be beneficial for patients to receive VAD for recovery of heart function or to facilitate bridging to heart transplantation.
In conclusion, coagulation will be significantly improved after bridge to VAD is completed. This improvement in coagulation complication from ECMO to VAD can be attributed to stable clot formation, thereby reducing the bleeding complication significantly. The success rate of heart transplants could be improved if bleeding was controlled by VAD.
